Table 2.
Relative chances of response and remission at Month 6.
| Esketamine NSa vs RW polypharmacy (95% CI); p value | |
|---|---|
| Response | |
| OR | 2.709 (1.930–3.802); <0.0001 |
| RR | 1.859 (1.474–2.345); <0.0001 |
| RD | 0.230 (0.159–0.301); <0.0001 |
| NNT | 5 (4–7) |
| Remission | |
| OR | 2.108 (1.449–3.067); 0.0001 |
| RR | 1.735 (1.297–2.322); 0.0002 |
| RD | 0.143 (0.078–0.207); <0.0001 |
| NNT | 8 (5–13) |
RW polypharmacy data were adjusted using the ATT covariate adjustment method. aGiven in combination with an SSRI or SNRI. OR > 1 indicates esketamine is superior to the comparator treatment. ATT, rescaled average treatment effect among treated; CI, confidence interval; NNT, number needed to treat; NS, nasal spray; OR, odds ratio; RD, risk difference; RR, relative risk; RW, real-world; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.